Announcements Trials
Browse Landscape

Phase

Phase 4 15Phase 3 10Phase 2 8Phase 1 8Phase EARLY_PHASE1 2Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Dermatologic 1

Conditions

Melanoma 1Hutchinson's Melanotic Freckle 1

Interventions

Nivolumab 7pembrolizumab 5Ipilimumab 4Interferon alpha-2 3relatlimab 2Etoposide 2Drug Therapy 2Dacarbazine 2Cyclophosphamide 2sargramostim 1salicylhydroxamic acid 1pertuzumab 1peginterferon alfa-2b 1peginterferon alfa-2a 1molgramostim 1green tea extract polyphenone E 1fludarabine phosphate 1entrectinib 1cyclopropapyrroloindole 1cobimetinib 1atezolizumab 1Whole-Body Irradiation 1Vincristine 1Vemurafenib 1VAP-cyclo protocol 1Triamcinolone Acetonide 1Trastuzumab 1Thiotepa 1Temozolomide 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Imiquimod × Dermatologic × Clear all
NCT01088737 2019-08-13

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Medical University of Graz

Phase 2/3 Unknown
60 enrolled
Dermatologic

Melanoma, Hutchinson's Melanotic Freckle

Data powered by HemOnc (CC BY 4.0) Colophon âš¡